重组人表皮细胞生长因子治疗烧伤创面研究

目的　探讨外用重组人表皮细胞生长因子 (rh EGF)治疗 度烧伤创面最佳用药方式。　方法　 2 0 0 0年6月～ 2 0 0 1年 12月对 6 0例浅 度和深 度烧伤患者共 180个创面进行随机双盲实验 ,每例患者设 A、B、C 3个治疗区。A区为 SD- Ag对照治疗区 ,1% SD- Ag霜涂创面 ,每日 1次 ;B区为 rh EGF治疗区 ,rh EGF4 0 U/ cm2 直接喷在创面上 ,每日 1次 ;C区为 rh EGF和速愈平混合治疗区 ,rh EGF4 0 U/ cm2和速愈平 5 g混合涂在创面上 ,每日 1次 ;每日观察记录 3个治疗区变化 ,直至创面愈合停止用药 ;愈合 1周后检查创面外观、皮肤弹性 ,并行统计学处理。　结果　浅 度创面 A区愈合时间为 (13.2 0± 2 .4 0 )天 ,B区为 (10 .2 0± 2 .2 0 )天 ,C区为 (8.72± 2 .31)天 ,组间比较有统计学意义 (P<0 .0 1) ;深 度创面 A区愈合时间为 (2 0 .10± 3.4 0 )天 ,B区为 (17.2 0± 3.12 )天 ,C区为 (15 .10± 3.81)天 ,组间比较有统计学意义 (P<0 .0 1和 P<0 .0 5 )。治疗期中 A区渗出液、创缘炎性反应均较 B、C区显著。深 度创面愈合后 B、C区无充血 ,有弹性和韧性 ;A区充血 ,无弹性和韧性。　结论　rh EGF对烧伤创面有明显促愈合作用 ,可改善愈合质量。rh EGF和速愈平联合使用对缩短创面愈合时间及提高愈合质量作用

A COMPARATIVE STUDY ON BURN WOUND HEALING TREATED BY DIFFERENT METHODS OF RECOMBINANT HUMAN EPIDERMAL GROWTH FACTOR

OBJECTIVE: To explore an optimal method of recombinant human epidermal growth factor(rhEGF) application on the burn wounds of superficial II degree and profound II degree for accelerating its healing. METHODS: There were 180 burn wounds in 60 patients with the self-corresponding wound of the same degree as controls. The wounds of all patients were divided three regions(A, B, C). The wounds were treated once a day with 1% SD-Ag in region A as controls, with rhEGF(40 U/cm2) in region B, and with a combination of rhEGF(40 U/cm2) and Su Yu Ping (5 g) in region C. The wound healing time was recorded and compared. RESULTS: In regions A, B and C, the healing time of superficial II degree wound was (13.20 +/- 2.40) days, (10.20 +/- 2.20) days and (8.72 +/- 2.31) days (P < 0.01); that of profound II degree wound was (20.10 +/- 3.40) days, (17.20 +/- 3.12) days and (15.10 +/- 3.81) days respectively (P < 0.01, P < 0.05). The healed wound of profound II degree was elastic and tough in regions B and C, while that was not elastic and tough, and congestive in region A. CONCLUSION: The above results indicate that rhEGF can enhance burn wound healing markedly and that a combination rhEGF and Su Yu Ping has more significant effect than rhEGF alone and is recommended for clinical application.